Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Price Target Raised to $27.00

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Free Report) had its price target increased by Morgan Stanley from $26.00 to $27.00 in a research note released on Monday,Benzinga reports. They currently have an equal weight rating on the biotechnology company’s stock.

A number of other equities analysts also recently commented on LKFT. TD Cowen initiated coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, November 13th. They set a “strong-buy” rating for the company. Weiss Ratings raised Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, October 2nd. Royal Bank Of Canada upgraded Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and raised their price target for the company from $26.00 to $45.00 in a research note on Wednesday, September 23rd. Raymond James Financial restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Thursday, November 12th. Finally, UBS Group raised Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.00.

Check Out Our Latest Report on Lakefront Biotherapeutics American Depositary Shares

Lakefront Biotherapeutics American Depositary Shares Stock Down 0.9%

NASDAQ LKFT opened at $34.07 on Monday. Lakefront Biotherapeutics American Depositary Shares has a 52 week low of $25.68 and a 52 week high of $36.24. The stock has a market capitalization of $2.25 billion, a PE ratio of -24.16 and a beta of 0.22. The firm has a 50 day moving average of $30.75 and a two-hundred day moving average of $29.94.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) last announced its quarterly earnings data on Wednesday, November 11th. The biotechnology company reported ($0.05) EPS for the quarter. The business had revenue of $7.87 million for the quarter. On average, equities research analysts expect that Lakefront Biotherapeutics American Depositary Shares will post 0.09 earnings per share for the current fiscal year.

Lakefront Biotherapeutics American Depositary Shares declared that its Board of Directors has approved a stock buyback plan on Monday, November 16th that authorizes the company to buy back $54.95 million in shares. This repurchase authorization authorizes the biotechnology company to repurchase up to 2.5% of its shares through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alps Advisors Inc. acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter valued at $2,617,000. Goldman Sachs Group Inc. purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter valued at $4,166,000. Marshall Wace LLP purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter valued at $2,326,000. Commonwealth Equity Services LLC acquired a new stake in Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter worth $279,000. Finally, Entropy Technologies LP acquired a new stake in Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter worth $887,000. Institutional investors and hedge funds own 32.46% of the company’s stock.

About Lakefront Biotherapeutics American Depositary Shares

(Get Free Report)

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.

See Also

Analyst Recommendations for Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)

Receive News & Ratings for Lakefront Biotherapeutics American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakefront Biotherapeutics American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.